SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMYLIN PHARM.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luis a. garcia who wrote (32)1/12/1997 10:46:00 AM
From:    of 52
 
These inside buys were part of the secondary that occured in Nov. Amyln was at $13 before the announcement and was dropping up to the pricing, where it was priced at $10. The public was able to but Amyln at 10 1/8 to 10 3/8 that day. Since, Amyln has come back to where it was before the secondary.

I like this stock and hope for good results when Phase III is completed. Long-term (`98-`99) I expect J&J to buy them out.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News